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Abstract
Introduction Acute gastroenteritis (AGE) is a common
and burdensome condition that affects millions of children
worldwide each year. Currently available strategies
are limited to symptomatic management, treatment
and prevention of dehydration and infection control; no
disease-modifying interventions exist. Probiotics, defined
as live microorganisms beneficial to the host, have shown
promise in improving AGE outcomes, but existing studies
have sufficient limitations such that the use of probiotics
cannot currently be recommended with confidence. Here
we present the methods of a large, rigorous, randomised,
double-blind placebo-controlled study to assess the
effectiveness and side effect profile of Lactobacillus
rhamnosus GG (LGG) (ATCC 53103) in children with AGE.
Methods and analysis The study is being conducted in
10 US paediatric emergency departments (EDs) within
the federally funded Pediatric Emergency Care Applied
Research Network, in accordance with current SPIRIT and
CONSORT statement recommendations. We will randomise
970 children presenting to participating EDs with AGE to
either 5 days of treatment with LGG (1010colony-forming
unit twice a day) or placebo between July 2014 to
December 2017. The main outcome is the occurrence of
moderate-to-severe disease over time, as defined by the
Modified Vesikari Scale. We also record adverse events and
side effects related to the intervention. We will conduct
intention-to-treat analyses and use an enrichment design
to restore the statistical power in case the presence of a
subpopulation with a substantially low treatment effect is
identified.
Ethics and dissemination Institutional review board
approval has been obtained at all sites, and data and
material use agreements have been established between
the participating sites. The results of the trial will be
published in peer-reviewed journals. A deidentified public
data set will be made available after the completion of all
study procedures.
Trial registration number NCT01773967.

Strengths and limitations of this study
►► This is a large multicentre randomised, double-

blind, placebo-controlled trial in a diverse and
geographically varied US population of children with
gastroenteritis.
►► We perform independent laboratory product testing
to assess probiotic viability, dosing and purity.
►► We use a statistical enrichment design to restore
the statistical power if a subpopulation with a
substantially low treatment effect is identified.
►► Outcome is based on parental report of symptoms
rather than direct observation
►► Enrolment is limited to day and evening hours only,
when research personnel is available.

Introduction
Acute gastroenteritis (AGE) is a leading cause
of malnutrition and death worldwide.1 Though
rarely fatal in North America, ~48 million
people in the USA contract AGE, and 128 000
are hospitalised annually.2 Although the
incidence of rotavirus infection in the USA
has decreased since the introduction of the
vaccine in 2006,3 norovirus is now the leading
cause of medically attended paediatric AGE
in this country.4 Unfortunately, current interventions are limited to rehydration, symptomatic management and supportive care
and prevention of severe dehydration and
secondary infections.5–8
Probiotics, defined as live microorganisms
that when administered in adequate amounts
are intended to confer health benefits on the
recipients,9 10 represent a novel approach to
improved management of paediatric AGE.
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Probiotics are generally considered to be safe, easily
administered and hypothesised to modulate disease
processes.11 Meta-analyses of various probiotic products
have reported reduced symptom durations in children
with AGE who have been treated with these agents.
However, the studies included in these analyses have
had important methodological limitations such as small
sample sizes, lack of probiotic quality control, outcomes
that are of minimal relevance to patients and their families and unclear randomisation, allocation concealment
and blinding and attrition biases.12–15 Remarkably, few
studies of probiotics have evaluated outpatients, a group
that represents the preponderance of AGE episodes in the
USA,16–18 and only one small study has evaluated probiotics in children with AGE presenting to a US emergency
department (ED), where no benefit was demonstrated.19
Given the lack of adequate efficacy and safety evidence,
most guidelines do not endorse the use of probiotics in
paediatric AGE.12 15 20–23 However, the European Society
of Pediatric Gastroenterology, Hepatology and Nutrition has offered a ‘strong’ recommendation in support
of specific probiotics to treat previously healthy children with AGE, despite their acknowledgement of the
‘low quality of the evidence’.24 Furthermore, probiotic
manufacturers aggressively market probiotics citing
health claims that have not been supported by rigorous
research,25–28 and the US market for digestive health
enzymes, prebiotics and probiotics was estimated at
US$495 million in 2015 and was expected to grow at
an annual rate of 13%.29 Despite these concerns about
their value, and issues surrounding safety and regulatory oversight,30–32 parents of patients with AGE often
administer probiotics to their children without guidance from medical professionals.9 22 We are therefore concerned that the consumption of probiotics is
increasing without adequate evidence to support their
use, which underscores the necessity of conducting
a definitive trial. There is strong consensus that an
adequately powered randomised controlled trial (RCT),
using a well-defined probiotic agent and comprehensive
and clinically sensible validated outcome measures in a
clinically relevant patient population will provide much
needed clarity to this field.12 15 33–35
Here, we report on the methodology of a double-blind
placebo-controlled pragmatic RCT (
ClinicalTrials.
gov:
NCT01773967), using Lactobacillus rhamnosus GG (LGG)
(ATCC 53103), the most available and studied probiotic in the USA as the intervention.36 37 The research is
supported by funding from the Eunice Kennedy Shriver
National Institute of Child Health and Human Development (NICHD R01HD071915) and is conducted under
the oversight of the Food and Drug Administration
(FDA investigational new drug 12371), in 10 US EDs
within the federally funded Pediatric Emergency Care
Applied Research Network (PECARN). The objectives
of this double-blind placebo-controlled RCT are to (1)
determine if, compared with placebo, LGG reduces the
severity of AGE episodes in children aged 3–48 months
2

presenting to an ED with AGE and (2) determine the
safety and side effect profile of LGG in children with
AGE.
We hypothesise that (1) in children with AGE, LGG
will be associated with a clinically meaningful decrease
in the proportion of children suffering from a moderate-to-severe episode of AGE defined by a validated Modified Vesikari Scale (MVS) score of ≥9, compared with
placebo, and (2) LGG will not be associated with serious
adverse events and will have a similar rate of side effects
(eg, bloating and fever) compared with placebo-treated
children.

Methods and analysis
Overview
This is a double-blind, 10-centre, paediatric ED-based
RCT conducted by the PECARN. Children aged 91 days
to <48 months who present to a participating ED between
July 2014 to December 2017 will be assessed for eligibility,
approached for informed consent and randomised to
receive 5 days of a probiotic (LGG 1010 colony-forming
unit (CFU) twice a day) or placebo. Physicians, patients,
study personnel and outcome assessors are blinded to
the intervention. LGG and the placebo are administered
twice daily. The study will be conducted and reported
according to the most recent SPIRIT and CONSORT
statement recommendations.38–40
Setting
Patients are being recruited at 10 US paediatric EDs
in PECARN (St. Louis Children’s Hospital (St. Louis,
Missouri, lead site), Lurie Children’s Hospital (Chicago,
Illinois), Cincinnati Children’s Hospital Medical Center
(Cincinnati, Ohio), Children’s Hospital of New York-Presbyterian (New York City, New York), Hasbro Children’s
Hospital (Providence, Rhode Island), Children’s Hospital
of Michigan (Detroit, Michigan), UC Davis Medical
Center (Sacramento, California), CS Mott Children’s
Hospital (Ann Arbor, Michigan) and the University of New
Mexico Children’s Hospital (Albuquerque, New Mexico).
Each centre has a strong research infrastructure and
successfully participated in multicentre ED-based trials.
Together the sites serve a large and diverse patient population. PECARN, the umbrella collaborative network, is
the first federally funded paediatric research network
in the USA and has an extensive record of successful
multicentre research41 The PECARN Data Coordinating
Center (DCC), based at the University of Utah, is responsible for data management and data analysis. An independent Data Safety Monitoring Board (DSMB) composed
of specialists in paediatric infectious diseases, paediatric
gastroenterology, paediatric emergency medicine and
biostatistics was formed to review enrolment, study procedures, case report form completion, data quality, loss to
follow-up, drop-in rate and interim safety and efficacy
results.
Schnadower D, et al. BMJ Open 2017;7:e018115. doi:10.1136/bmjopen-2017-018115
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Inclusion criteria and rationale
1. Presence of diarrhoea: defined as ≥3 watery stools in
the 24 hours prior to assessment,42 with or without
vomiting (vomiting alone, which may be the sentinel
sign of AGE, could also represent non-infectious
illnesses and is therefore not a sufficient criterion to
qualify for eligibility).
2. Duration of vomiting or diarrhea ≤7 days: as we are focusing on acute diarrhoea, which typically is of less than
7 days’ duration.18 It is unclear if probiotics are useful
in the early or later stages of AGE,19 our enrichment
design will allow for adaptive randomisation if a particular group is more likely to benefit from treatment.
3. Age 91 days–<48 months: AGE severity and frequency
are greatest among young children,43 including those
who visit North American EDs.17 44 45
4. Symptoms consistent with AGE per treating physician: this
is to ensure that only children with a presumptive
diagnosis of AGE are included in the study.
Exclusion criteria and rationale
1. Presence of an indwelling vascular access line or structural
heart disease: potential bacteraemia risk with
intervention.46
2. Receiving immunosuppressive therapy, or history of
immunodeficiency: potential bacteraemia risk with
intervention.47
3. Haematochezia: (studies show little efficacy of
probiotics in children with bacterial AGE, and visible
blood in the stool is a marker for such pathogens).48 49
4. Chronic gastrointestinal problems (eg, short gut
syndrome and inflammatory bowel disease): diarrhoea
in such children is more likely to be related to noninfectious causes.
5. Critically ill patients or patients admitted to the intensive
care unit: these patients are at risk of invasive disease,
and their ability to comply with an oral intervention
might be limited.
6. Household member with an indwelling vascular access
line, on immunosuppressive therapy or with a known
immunodeficiency: risk for invasive disease if there is
intrahousehold dissemination of the LGG (note that
this exclusion does not extend to household contacts
who use a short course (<7 days) of oral steroids or
are using inhaled steroids).
7. Bilious emesis: might indicate a diagnosis other than
AGE.
8. Probiotic use (supplement) in the preceding 2 weeks:
confounding risk; consumption of foods containing
probiotics will not result in exclusion as they are
ubiquitous.
9. Previously enrolled in this trial: to ensure that the
observations are independent.
10. Daily telephone follow-up not possible while symptomatic:
avoid loss to follow-up because of travel plans or
language barrier.
11. Allergy to Lactobacillus or microcrystalline cellulose
(MCC): contents of capsule and placebo.
Schnadower D, et al. BMJ Open 2017;7:e018115. doi:10.1136/bmjopen-2017-018115

12. Allergy to beta-lactam antibiotics, erythromycin and
clindamycin: these antibiotics might be used in the
event of LGG extraintestinal dissemination.
Children taking antibiotics will not be excluded because
probiotics remain viable when given concomitantly with
antibiotics, and the survival of the active bacterial strains
is not diminished.50
Participant allocation
Sequence generation
The PECARN DCC produced randomisation lists, stratified by study site and duration of symptoms, using
random number-generating software. The lists were sent
to the central pharmacy (Cincinnati Children’s Hospital
Medical Center) that prepares consecutively numbered
study kits according to the randomisation schedule.
These are sent by courier to the clinical sites where they
are stored in the research support pharmacies.
Allocation concealment
Randomisation was performed at the DCC using random
block sizes with a 1:1 allocation ratio. Stratifying by clinical site ensures that variations (eg, site-specific practice
patterns and gastrointestinal pathogens) are comparably
distributed across treatment arms. Only the DCC retains
the randomisation code. Unblinding can be requested
by treating medical personnel in case of an emergency
requiring such information.
Implementation
Potentially eligible patients are identified by triage nurses
at each site who contact the research assistant (RA). The
RA then (1) screens patients for eligibility, (2) maintains
a log of all screened patients, (3) discusses the details of
the study with the caregivers of all eligible children, (4)
obtains consent, (5) enrols children, (6) consecutively
assigns a patient identification number, (7) randomises
the patient (using a web-based system: www.randomize.
net), (8) collects baseline demographic clinical variables and (9) in conjunction with the treating physician,
completes data collection forms.
Intervention
LGG and placebo capsule contents
LGG, ATCC 53103 is supplied in a gelatin capsule
containing 1010 CFU LGG. Each LGG capsule contains
75 mg of LGG and 250 mg of MCC, an inert ingredient.
The placebo capsules contain only MCC (325 mg). Each
capsule is wrapped in double foil to protect it against
light, air and moisture. Blister packs are labelled with the
lot number. LGG and placebo capsules and powder are
identical in appearance, taste, texture and odour. LGG
capsules and placebo capsules have active Drug Master
Files at the FDA (BB-MF 213 668 and MF2 13 646, respectively). The dose and duration of therapy are based on
the currently available evidence.51–63
ED intervention
The patient’s nurse administers the first dose of either
LGG (1010 CFU/dose) or placebo on site by sprinkling
3
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the capsule’s contents into 30 mL of room temperature,
non-carbonated liquid. The RA provides caregivers with
verbal and written instructions regarding (1) study drug
administration; (2) completion of study forms; (3) what
and how much fluid to drink; (4) criteria for seeing a
healthcare practitioner or returning to the ED; and (5)
standardised AGE discharge instructions and letter to
their primary care provider explaining the study. All
other aspects of medical care will be at the discretion of
the treating physician.
Home intervention
All patients consume one capsule of LGG or placebo,
based on randomisation, every 12 hours for 5 days (1010
CFU twice daily × 5 days, for a total of nine home doses).
Patients receive the medication at meal time, mixed with
30 mL of a room temperature non-carbonated liquid
and ingested immediately to optimise probiotic viability.
Oral fluid therapy is encouraged according to established
guidelines.21 The study protocol is continued in the subset
of children (estimated <5%) who are hospitalised.18 Also,
caregivers are provided with a letter to share with their
primary care provider (in case they visit their provider
during the course of the study). The letter describes the
study and the care plan, and it includes site investigator’s
contact information and the importance of adhering to
the study protocol. Patients may withdraw from the study
at any time based on their or their physician’s discretion; however, efforts will be made to proceed with safety
follow-up, and the subjects will be included in the intention-to-treat (ITT) analysis.
Stool sample testing
Stool samples (swab or bulk stool, as available) from
all enrolled children are collected, frozen and sent to
Washington University – St. Louis Children’s Hospital
Virology Laboratory and tested with multiplex PCR
using the Luminex xTag Gastrointestinal Pathogen Panel
(Luminex, Austin, Texas, USA), which identifies the
following organisms (and specific bacterial loci): viruses:
norovirus (GI and GII), adenovirus F 40/41 and rotavirus
(A); bacteria: Escherichia coli O157, enterotoxigenic E. coli
(lt/st), Shiga toxin-producing E. coli (stx1/stx2), Vibrio
cholerae, Shigella spp., Salmonella spp., Campylobacter spp.,
Yersinia enterocolitica and Clostridium difficile (tcd A/B); and
parasites: Cryptosporidium spp., Giardia spp. and Entamoeba
histolytica.
In addition, St. Louis Children’s Hospital and the
New Mexico Children’s Hospital collect and freeze bulk
stool specimens in the acute phase (within 24 hours of
presentation) and following resolution (14 days after
presentation) using a home stool collection protocol.
The protocol consists of providing the family with a specimen collection kit, gel packs and an insulated envelope
at enrolment. When the specimen is ready for collection, a courier retrieves the specimen and cool pack at
the patient’s home and delivers it to a logistics collection
centre. The stools are frozen on receipt in St. Louis and
4

Albuquerque, and then stored in the Tarr Laboratory at
Washington University at −80°C for future testing.
Data Collection
All caregivers receive discharge instructions that include
information on tasks required following discharge along
with a diary to record daily symptoms and all information
requested during the telephone calls or electronic surveys,
including side effects (see supplemental file: follow-up
surveys). Follow-up occurs daily until symptoms resolve or
5 days, whichever occurs later, and again at 14 days and 1,
3, 6, 9 and 12 months following enrolment. Data collected
daily and at day 14 follow-up are used to measure efficacy
and short-term safety outcomes. Long-term follow-up
data (1 month onwards) are used to assess long-term
adverse events, unanticipated medical encounters and
development of new chronic illnesses in accordance to
FDA guidelines (Guidance for Industry and Investigators:
Safety Reporting and Requirements for INDs and BA/BE
Studies).64 We use a standardised script and data collection forms to obtain follow-up information by telephone
or via email survey. Follow-up procedures are centralised
at the lead site. We also perform chart reviews to verify
data regarding revisits, intravenous hydration, hospitalisation and microbiology testing using each centre’s medical
record database. Personal data will be handled in compliance of the Health Insurance Portability and Accountability Act. Data are entered in to encrypted and secure
central databases managed by the DCC at the University
of Utah, where state-of-the-art equipment and procedures
ensure data quality and security.
Compliance
We assess patient compliance with therapy on day 5 and
collect final data on day 14. To maximise compliance,
caregivers are reminded of the importance and method
of administering the probiotic/placebo. A similar scheme
has been used in our previous studies.18 65–67
Probiotic quality control/independent testing
We test samples of all batches of probiotic product at an
independent laboratory twice a year until expiration date
to ensure adequate bacterial counts. In order to maximise bacterial viability, probiotic products are kept refrigerated at research pharmacies between 0°C and 4°C.
Shipping and storage logs are retained.
Study monitoring
The DCC coordinated site (in-person and remote) monitoring as well as pharmacy monitoring at the beginning
and once during the study. The monitor has provided
each site with a written report, and sites have been
required to respond to and resolve deficiencies. Sponsoring and regulatory agency monitoring is at the discretion of such agencies.
Outcome measures
The primary outcome to measure efficacy is the presence of moderate-to-severe AGE, as defined by a total
Schnadower D, et al. BMJ Open 2017;7:e018115. doi:10.1136/bmjopen-2017-018115
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Table 1 Modified Vesikari Score
Points

0

1

2

3

Diarrhoea duration
Max no. of diarrhoeal stools/24 hours

0
0

1–96 hours
1–3

97–120 hours
4–5

≥121 hours
≥6

Vomiting duration

0

1–24 hours

25–48 hours

≥49 hours

Max no. of vomiting episodes/24 hours

0

1

2–4

≥5

Max recorded fever

≤37°C

37.1–38.4°C

38.5–38.9°C

≥39°C

Unscheduled healthcare visit

0

–

Treatment

None

Rehydration

Primary
care
Hospital
admission

Emergency
department
–

postenrolment MVS score ≥9 during the 2-week follow-up
period (table 1). This scale has been validated in our
patient populations.18 45 Each of the seven items in the
scale is tabulated individually (maximum of 20 points);
the sum of these individual variables represents the total
MVS score. At the time of randomisation (time 0), a
pre-enrolment MVS score is assigned based on symptoms
prior to presentation. This score serves as a covariate in a
secondary analysis of the primary outcome. The postenrolment MVS score used to determine the presence/
absence of the primary study outcome, is based only on
symptoms that occur between time 0 (ie, randomisation)
and the conclusion of the study period (ie, day 14). The
postenrolment score is calculated only once, on day 14.
At that time, each of the seven variables are assigned a
score for the entire study period (time 0 to day 14). Each
variable is scored in 1 of 3 methods: (1) worst 24 hours
period—maximal number of episodes of vomiting in
a 24-hour period, maximal number of episodes of diarrhoea in a 24-hour period and maximal temperature); (2)
total duration of symptoms, including the number of days
on which any gastroenteritis-related symptom occurred.
For scoring purposes, the episode of AGE concludes
after absence of symptoms for 24 hours; and (3) occurrence of an outcome—treatment and subsequent healthcare utilisation. A score of ≥9 defines moderate-to-severe
disease because on the original score, severe disease was
defined as ≥1168–72 and moderate as ≥9.73 In our derivation and validation pilot studies,18 45 construct validity
was demonstrated and validated by using scores of ≥9 to
define moderate and ≥11 to define severe disease. These
cut-points were associated with significant increases in
other measures of disease severity such as degree of dehydration, likelihood of admission and daycare and parental
work absenteeism.18 45
Main safety outcome
The main safety outcome is the occurrence of extraintestinal infection by the administered probiotic agent—
LGG. Based on previous human experience with LGG in
healthy volunteers, pregnant women, neonates and children with AGE, we do not anticipate that any extraintestinal infections will occur. Adverse event analysis will follow
Schnadower D, et al. BMJ Open 2017;7:e018115. doi:10.1136/bmjopen-2017-018115

FDA guidelines for assessment of attribution, toxicity
grading scale and criteria for patient withdrawal. Per FDA
recommendations, we conducted an interim safety analysis after the first 80 patients, including 40 less than 1 year
of age, had completed their 1-month follow-up.
Secondary outcomes (efficacy)
Secondary outcomes include the following: (1) diarrhoea
duration: time from treatment initiation until the appearance of the last watery stool as reported during daily phone
conversations, (2) vomiting duration, (3) return visits
for unscheduled care to a healthcare provider related to
vomiting, diarrhoea, dehydration, fever or fluid refusal,
within 2 weeks of the index visit. We will not include
scheduled visits (eg, reassessment, vaccinations and unrelated issues). This outcome is important because >50% of
children with AGE have a follow-up office visit,16 8%–18%
require an ED visit and 5%–8% are hospitalised.16 (4) Days
of daycare missed by subjects, (5) days of work missed by
caregivers and (6) household transmission rate: a household census is obtained at the time of enrolment, and we
obtain information about incident household symptoms
during the telephone follow-up calls. Secondary transmission is an integral feature of AGE, and households are
relevant and well-established study units.74–76
Secondary outcomes (safety)
The secondary safety outcome is the presence of potential side effects such bloating, gas, intestinal rumbling,
diarrhoea, blood in stool, abdominal pain, abdominal
cramps, nausea, vomiting, loss of appetite, abnormal taste,
heartburn, constipation, skin rash, fever, nasal congestion, sore throat, cough, headache, malaise, muscle
aches and chills. We acknowledge, however, that some
toxicities will be difficult to distinguish from abdominal
symptoms related to the AGE, and only at the time of data
analysis will we be able to determine if these signs and
symptoms differ between the groups (ie, by comparing
the differences in occurrence between the active and
placebo groups). The study physicians complete the
appropriate form for all adverse events identified during
the scheduled or unscheduled phone calls. During longterm follow-up telephone calls (ie, those occurring after
5
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14 days postenrolment), we inquire about unexpected
events obligating medical attention and new onset of
chronic disorders, especially those involving the digestive
system.
Data analysis and sample size
All analyses will be undertaken by the ITT principle,
except for side effects, which will use the ‘as-treated’
principle (compare the subjects based on the treatment
regimen that they received). Patients who withdraw,
drop out or crossover will be followed and included in
the ITT analysis. All statistical tests of hypotheses will be
two sided. For cases where information needed to derive
the primary outcome is incomplete, we will use multiple
imputation methods. The proportion of children with
moderate-to-severe disease (ie, MVS ≥9), the primary
outcome will be analysed by comparing proportions using
a Mantel-Haenszel test, stratified by participating centre
and duration of symptoms prior to presentation. Significance for this primary outcome measure will be set at
0.05. Secondary analyses of the primary outcome will use
logistic regression methods to adjust for covariates (eg,
age, pre-enrolment MVS, hydration assessment and need
for hospitalisation at index visit). We will also analyse the
outcome using MVS as a continuous variable through a
stratified Wilcoxon rank-sum test and compare the results
with the primary analysis.
The overall significance level for statistical tests on the
secondary outcomes will be set at 0.05. Holm’s method
will be used to adjust for multiple comparisons.77 The
continuous variables of durations of (1) diarrhoea and
(2) vomiting will be measured in hours and analysed with
a Van Elteren test78 and stratified by clinical centre and
duration of symptoms. Similarly, the number of days (3)
the child is absent from daycare and (4) the caregiver
is absent from work will be analysed with a Van Elteren
test, stratified by clinical centre and duration of symptoms. Dichotomous outcomes to be evaluated include ED
AGE-related revisits, intravenous rehydration and hospitalisation. These six outcomes will be jointly assessed for
significance using Holm’s method. Additional analyses
involving these outcomes will include linear and logistic
regression models that adjust for possible effects of baseline characteristics. The proportions of children experiencing (5) an unscheduled healthcare visit or (6) any
potential adverse effect, as reported by the caregivers, will
be compared between groups using the Mantel-Haenszel
test, stratified by site and duration of symptoms. The analysis will evaluate the presence/absence of prespecified
side effects, as an aggregate outcome variable. A per-protocol analysis will be conducted to provide additional
insight as non-compliance may result in an underestimation of the benefits of probiotics in the ITT analysis.79
Power analysis
The primary analysis will be performed on a binary
outcome: development of moderate-to-severe disease.
The power of this analysis depends on the proportion of
6

Table 2

Power analysis.

Outcome
control

Outcome
intervention

% Difference

Power

0.30
0.30

0.21
0.20

9
10

0.76
0.85

0.25

0.15

10

0.90

0.25

0.16

9

0.82

0.25

0.17

8

0.72

0.20

0.10

10

0.95

0.20
0.20

0.12
0.13

8
7

0.81
0.69

Highlighted area corresponds to stated assumptions in the text.

patients with moderate-to-severe disease in each group
considered. Data collected as part of our pilot evaluations of the MVS in 729 children aged 3–48 months
demonstrated that when using the ED visit as time 0, 25%
of eligible children had scores consistent with moderate-to-severe disease following discharge.18 45 This is a
lower rate than previous reports of diarrhoea in paediatric EDs69 70 and in the community68 71 73 but is attributed
to our exclusion of symptoms that existed prior to the
visit. Because both the populations and method of MVS
calculation in the MVS derivation and validation studies
and the current proposal are identical, 25% is supported
by data from our pilot study and is likely to be accurate.
To determine the minimal clinically important difference
that we should aim to detect, 10 content experts were
surveyed. Absolute risk differences ranging from 7.5% to
15% were suggested. We selected a conservative estimate
of 10% for the primary outcome (ie, number needed to
treat of 10). For the current study, our sample size calculation assumed a 25% event rate in the control group,
and we desire to detect an absolute beneficial treatment
effect of 10% with 90% power. Using a two-sided type
I error (α) of 0.05 and the hypothesised proportions
yields a required total sample size of 670 patients.80 Our
expected power, if true event rates in our two groups
differ from those expected, is presented in table 2. Based
on prior work by our group,18 45 65 81 82 we assumed 10%
loss to follow-up (adjustment: 670/0.90=744), 5% drop
out and 3% drop in rate (caregivers who buy a probiotic agent to administer to their child) (adjustment:
744/ (0.92)2=879). Adjustment for O’Brien-Fleming
monitoring boundaries requires a further 2% increase.
Thus, the total number randomised (final sample size)
is therefore 900. In the fall of 2015, however, 36 patients
were potentially exposed to a batch of LGG that was later
found to contain inadequate bacterial counts on independent testing. We assumed that approximately 18 of
these were exposed and having the same effect as dropouts. In order to maintain study power under this worstcase scenario, we would have to increase the sample size
to 970 patients (900/(0.963)2, where 0.963 is 1 minus
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the drop-out rate of 18/485=0.037). Based on preliminary surveys, we believe that achieving this sample size is
feasible at our sites.
(1) Formal subgroup analyses will be based on (a)
age <1 year, (b) antibiotic usage, (c) infectious agent
(virus, bacteria, parasite or other). Treatment effect
will be summarised across subgroups. A subgroup effect
will be declared to be significant only if the interaction
between treatment and the subgroup factor is significant in an appropriate statistical model (including multivariate regression analyses), using a significance level
of <0.05/3=0.017 for each. (2) Duration of vomiting will
be analysed only in those subjects reporting ≥3 episodes
of vomiting in the 24 hours preceding enrolment. (3)
Daycare and work absenteeism will only be analysed for
those subjects who attend daycare and/or whose caregivers work outside of the home.
Enrichment design
The above study design and power analysis are based on
the assumption of homogeneous treatment effect. We
incorporated an enrichment design83 84 to restore the
statistical power if a subpopulation with a substantially
low treatment effect is identified. We are particularly
interested in two potential subpopulations: participants
with <2 days of symptoms and those with ≥2 days of
symptoms. Based on our pilot data, each subpopulation
accounts for approximately 50% of the total population. The decision for enrolment modification was made
at the first interim analysis for efficacy (350 enrolled
patients). Specifically, three statistics (based on a normal
approximation of binomial distribution or z-statistics) were calculated to compare the primary endpoint
between treatment and control groups for subjects in
the total population and the two subpopulations, respectively. If the z-statistic from a subpopulation is <0.3 and
also smaller than that in the total population, subjects
from this subpopulation are no longer to be considered
in the subsequent enrolment. All subjects, regardless of
symptom duration are to be included in the final analyses. Our simulation studies have showed that such an
enrichment design can increase the power considerably
when the treatment effects are different across subpopulations, while it will have little impact on power when
the treatment effects are similar. Following these analyses
performed after 350 patients were enrolled and recommendations by the DSMB, the decision not to modify
enrolment was made.

Frequency of analysis
The DSMB met after 80 (safety at 1 month), 350 and 650
subjects had completed their 1-month follow-up assessments to review enrolment, study procedures, case report
form completion, data quality, loss to follow-up, drop-in
rate and interim safety and efficacy results. The analyses
tested the hypothesis that the probability of developing
moderate-to-severe AGE in the probiotic arm is equal to
that in the placebo arm. Conservative O’Brien-Fleming
monitoring boundaries, implemented using the Lan-DeMets alpha spending function approach, will be used as
guidelines for early stopping for efficacy. At each step,
the DSMB recommended that the study continue without
modifications (table 3).
Ethics and dissemination
This trial is being conducted under an Investigational
New Drug application approved by the FDA (Investigational New Drug application 15371). Institutional review
board (IRB) approval has been obtained at all sites.
Financial compensation is provided to compensate for
parents’ time completing follow-up. This compensation
was approved by each site’s IRB. All important modifications will be communicated to the pertinent parties. Data
use agreements have been obtained between all sites,
and the DCC and Material use agreements have been
obtained between all sites and the lead site. The results
of the study will be published in peer-reviewed journals.
A deidentified public data set will be made available after
the completion of all study procedures. The study investigators will have access to the final trial data set. Authorship will be conferred per the International Committee of
Medical Journal Editors.

Discussion
This is the largest RCT of probiotics in children
presenting with AGE to an ED to date. We propose
to improve outcomes in children affected by AGE by
modifying the disease process through biologically plausible mechanisms. Translating this knowledge into a
disease-modifying clinical intervention would represent
a major change in the approach to this burdensome
illness and provide clarity to clinical practice that has
been hindered by aggressive marketing in the absence of
valid data. Critical elements incorporated into our design
that were absent in earlier studies are: (1) evaluating a
specific regimen in a large number of participants in a

Table 3 Interim analyses stopping rules
Analysis

Two-sided p Value

Probability of stopping
(80% power) (%)

Probability of stopping
(90% power) (%)

First (350 patients)
Second (620 patients)
Final

<0.0007
<0.014
<0.046

4.9
40.2
34.9

8.5
51.2
30.4
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geographically diverse network in the USA, (2) using a
meaningful and validated outcome in our population, (3)
identifying infectious causes, (4) using adaptive randomisation to target specific subgroups and (5) accounting for
pre-evaluation administration of probiotics. We attempt to
minimise bias by adhering to the 2013 SPIRIT guidelines
and the 2010 CONSORT Statement recommendations
including the use of ‘third-party’ assignment.38 Placebo
capsules and active drug are provided by I-Health Inc.
The probiotic and placebo capsules and powder are identical in appearance, taste, texture and odour. Participants,
families, healthcare providers, data collectors, outcome
adjudicators and data analysts are blinded as to intervention arm, thereby preventing bias in outcome assessment. An ITT analysis will be performed to minimise
bias associated with poor compliance and non-random
loss of participants.85 Cointerventions (eg, antiemetic
administration and intravenous rehydration) and other
potential sources of confounding are recorded. Our use
of a published validated score as an outcome measure
protects against the introduction of bias in the assessment
of treatment effects.86
Of note, a similar study using a different probiotic
product containing Lactobacillus rhamnosus and L. helveticus
(Lacidofil) is being conducted in Canada with funding
from the Canadian Institutes of Health Research.87 This
parallel study provides opportunities to enhance our
knowledge about the effect of probiotics in children with
AGE.

Conclusion
This double-blind, placebo-controlled RCT will quantify the benefits and potential side effects associated
with probiotic administration in ambulatory children
presenting to the ED with AGE. This will provide the first
definitive evidence in the USA for or against using probiotic therapy for this condition and establish the safety of
the intervention. The results of this multicentre study will
guide the standard of care: if probiotic administration is
associated with benefit, it offers a relatively inexpensive
and safe to administer treatment to reduce morbidity
from AGE. If the trial does not demonstrate probiotic
efficacy, healthcare and family and societal resources may
be refocused on different interventions.
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